Piper Sandler Raised the Firm's PT on ABIVAX Societe (ABVX), Kept an Overweight Rating

ABIVAX Société Anonyme (NASDAQ:ABVX) is one of the Best All-Time High Stocks to Buy According to Analysts. On July 29, Piper Sandler raised the firm’s price target on ABIVAX Société Anonyme (NASDAQ:ABVX) from $70 to $112, while keeping an Overweight rating on the stock.

The upgraded price target comes after the firm analysed Phase 3 induction data for ABIVAX Société Anonyme’s (NASDAQ:ABVX) drug Obefazimod in ulcerative colitis. The firm also noted that it is fair to add the revenue potential from early-line UC treatments, which doubles its US UC revenue forecast to €2,656 million by 2035.

The analyst believes there is significant upside for the ABIVAX Société Anonyme (NASDAQ:ABVX) ahead of key upcoming data releases. This includes full induction data presentations and maintenance data expected in 2026.

ABIVAX Société Anonyme (NASDAQ:ABVX) is a clinical-stage biotechnology company that develops treatments for chronic inflammatory diseases like ulcerative colitis and Crohn’s disease.

While we acknowledge the potential of ABVX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.